ALPHAREDISOL

Post-LOE

hydroxocobalamin

Merck & Co.

ANDAINJECTIONINJECTABLE

Approved

Apr 1975

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ALPHAREDISOL (hydroxocobalamin) by Merck & Co. is clinical pharmacology vitamin b 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis. Approved for multiple sclerosis, anemia. First approved in 1975.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Vitamin B 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis. Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the…

Indications (2)

multiple sclerosis anemia

Worked on ALPHAREDISOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.